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Portugal’s 2001 Drugs Liberalisation Policy: A UK service provider’s perspective on the 
Psychoactive Substances Act (2016) 
 
Abstract 
 
The Misuse of Drugs Act (1971) and the Psychoactive Substances Act (2016) both reinforce 
the criminalisation of drugs use in the UK.  The Psychoactive Substances Act (2016) has 
been developed to control and monitor the use of legal highs, particularly in institutions. This 
study aimed to establish drug service providers’ viewpoints on how effective UK drug 
policies have been at curtailing criminal behaviours and whether existing policies should be 
aligned with the Portuguese drug liberalisation policy. A thematic analysis was conducted 
following semi-structured interviews with four UK based substance use service providers. 
Two superordinate themes emerged and included a need for change in UK drug policy 
including a clearer definition of the Psychoactive Substance Act (2016) and an integrated 
systems approach to drug policy in line with the Portuguese liberalisation policy.  This would 
curtail the criminalization of drug users, target those with substance misuse problems in the 
community and in prison, and support an attuned systems approach to treatment.   
 
Introduction  
 
The Misuse of Drugs Act (MDA, 1971) is the primary legislation for controlling 
psychoactive substances in the UK and is distinguished by ABC classes of their harmfulness. 
An estimated 500 substances are controlled via the MDA (Reuter, 2011). The Advisory 
Council on Misuse of Drugs (ACMD) was developed to guide the MDA regarding the harms 
associated with psychoactive substances. Despite efforts of the UK Drug Policy Commission 
(UKDPC) to establish an evidence based approach to the MDA classification, the ABC 
classification is unsupported with scientific evidence (Nutt, 2009).  For example, a study 
conducted by Chandler et al. (2014) found that UK authorities prioritise opioid (class A) use 
as a drug-related problem to be addressed within the community borders through substitution 
therapy and residential programs, but benzodiazepine (class C) abuse is a common problem 
among young parents, especially pregnant women, yet remains largely ignored (Chandler et 
al., 2014). 
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The Psychoactive Substances Act (2016) has been developed to curtail the use and supply of 
legal highs. The manufacture and availability of legal highs is diverse where developing a 
suitable classification system under the Misuse of Drugs Act (1971) to criminalise these 
drugs is a proven challenge. The Psychoactive Substances Act (2016) states that headshops 
will be the focus of enforcement (Home Office, 2016). However, easy access to these 
substances via the internet will prove harder to monitor and control compared to headshops. 
Further, what constitutes a legal high is difficult to define and many of the challenges which 
presented the MDA will no doubt become apparent to the Psychoactive Substances Act 
(2016).  According to this act, one is prohibited from “producing, supplying, offering to 
supply, possessing with an intent to supply or within places of custody, importing or 
exporting of any substance intended for human consumption that is capable of producing a 
psychoactive effect” (Nutt, King & Phillips, 2010).  The Psychoactive Substances Act (2016) 
does not criminalise those in possession of legal highs (personal use) unless those in 
possession are in an institution, namely prison.  
 
In part, the UK’s drug policy’s stem from the 1980s-1990s which was geared towards public 
health protection. Because of the growing incidence of HIV and hepatitis among the 
intravenous-injecting drug users, policymakers ensured the accessibility of needle exchange 
schemes and health education for the at-risk population segment (Monaghan, 2012). This 
period was characterised by treatment-focused harm reduction interventions. In 1995, the UK 
Tackling Drugs Together policy involved harsh criminalisation due to the high-level of drug-
related criminal statistics (Monaghan, 2012). However, Hughes and Stevens (2010) argued 
that harsh criminalisation is a possible panacea for society, regardless of scientific evidence 
stating the opposite, and the fear that any steps towards decriminalisation would have “sent 
the wrong message” to the public (p. 999). In this respect, Newcombe (2008) has termed the 
UK drug policies as a “drug war.”  Indeed, the debate on drug policy remains polarised where 
the ‘war on drugs’ perpetuates the opinion of controlling drugs via the Misuse of Drugs Act 
(1971) and in part the Psychoactive Substances Act (2016).  
 
In contrast, other Countries have employed alternate methods of control and enforcement. To 
expand, decriminalisation of being in drug possession for personal use includes Portugal, 
Czech Republic, Brazil and Bolivia (Feiling, 2011). Indeed, the Portuguese 15-year 
experience of decriminalisation of drugs has been widely promoted as a relevant strategy to 
eliminate the UK’s ‘war on drugs’ through the adaptation of this policy framework (Feiling, 
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2011). Decriminalisation refers to “a new response to drug offences through administrative 
processes where “drug addiction is a health issue and not a criminal one” (Ponte, 2015, p. 
18). As a result, the Portuguese approach entails that the individuals are allowed to acquire, 
possess and personally use psychoactive drugs, including cannabis, in small quantities, 
without being prosecuted (Greenwald, 2009; Laqueur, 2014). Other countries including for 
example the Netherlands, Spain and Italy have utilised civil rather than criminal penalties for 
those in drug possession.   
 
Whilst the research to support decriminalisation remains contested, it appears that the drug 
problems in these Countries have not increased. Woods (2011) emphasised that Portugal has 
developed a well-shaped background for the implementation of the strategy which was aimed 
at reducing drug-related harm and criminal prosecution. This employs a pragmatic and 
humanistic approach, which prohibit the stigmatisation of drug users, and involves the 
Commission for the Dissuasion of Drug Addiction (CDT). CDT comprises of legal 
representatives along with medical and social workers.  Police officers are largely not 
involved in the process, unless there is a need to confiscate the drugs. Therefore, the 
Portuguese approach is distinct from that in the UK. The Portuguese model makes drug users 
the centre of an integrated circle of collaboration and favours a systems approach. For 
example, the approach has supported rehabilitation services, housing and social security 
measures (Greenwald, 2009; Laqueur, 2014) where reports have confirmed a decrease in the 
use of problematic drugs and subsequent criminal offending behaviours (Greenwald, 2009). 
Additionally, Murkin (2014) suggests that Portuguese drug use rates and drug related deaths 
are lower than in Europe. Further, the number of arrests has decreased from 14,000 as a 
2000-year indicator to 5,000-6,000 in the late 2000s and the number of the incarcerated 
criminals due to drug-related issues reduced from 44% to 21% between 1999 and 2012. 
 
Felix and Portugal (2015) have explored the efficacy of the drug policies aimed at the 
decriminalisation of illicit drugs. The authors have analysed the trends of market prices for 
cocaine and opioids for 10 European countries, with Portugal as the centrepiece, and have 
discovered that the assumption is not always valid (Felix & Portugal 2015). Woods (2009) 
argues that decriminalisation will explicate potential economic advantages in a form of taxes 
and new business ventures among others rather than lead to drug-related violence. According 
to Humphreys (2013), McKeganey (2007) and Newcombe (2008), policymakers need to 
develop appropriate policy initiatives in conjunction with the local scientific research and in 
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collaboration with local professionals. Having an understanding of the mental health 
implications of drugs use especially via primary line professionals are critical input in 
supporting a systems approach and in the development of evidence based informed policies. 
This is an important consideration when looking at illicit drug use in the UK. The Office for 
National Statistics (ONS) (2016) has shown that approximately 8.6% of adult individuals 
within the 16-59-year age gap used an illicit drug during 2014-2015, while this percentage in 
2004/2005 comprised more than 11.2%. The same indicator for UK residents aged between 
16 and 24 was 19.4% and 26.5% respectively (ONS, 2016, p. 1). The use of drugs including 
legal highs and ecstasy for youths aged between 16 and 24 years has increased from 3.9% in 
2004/2005 to 5.4% in 2014/2015 (ONS, 2016, p. 1). Although the above information may 
have evidenced a slight reduction in illicit drug use, drug-related crimes appear to have 
increased.  
 
Lefebvre (2015) suggests that the Psychoactive Substances Act (2016) involves the “use of 
drugs is an evil to eradicate, thanks to hard laws efficiently enforced” (Lefebvre 2015, p. 
477). The other notable perspectives on anti-drug measures are reliance on physiology and 
treating the drug-related issues by doctors as well as reference to social domains and the 
elimination of the problem in a complex manner (Lefebvre 2015). Drawing upon the 
controversial and contradictory statistics, the current update to the UK drug policies seems to 
be an unjustified step, since criminalisation has not led to a decrease in criminally offending 
behaviours. Significant costs are spent on the detention of prisoners which provided a 
breakdown of the expenditure on drug related crime reported by police in England and Wales 
for the period of 2011/12. From an individual perspective, use of drugs accounts for annual 
expenditure of £15,000-£30,000 per single user, while the number of crack and heroin users 
in England alone is approximately 306,000 individuals, out of which around 200,000 people 
undergo rehabilitation courses on an annual basis (Bennett & Holloway, 2009).  
 
The changing trends of drug use in prison also highlights concerns over the Psychoactive 
Substances Act (2016). Whilst reduced levels of illicit opiates (excluding medication) are 
being observed in prison (former HM Inspectorate, 2015) the same cannot be said for 
synthetic cannabis and additional legal high substances. Since being in possession of legal 
highs is illegal in prison, this holds important implications regarding parole, the added costs 
of drugs in prison along with additional concerns such as mental health problems and 
overcrowding (Hawton et al.2013; Ministry of Justice2008, 2012, 2013a, b; HMP 
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Inspectorate of Prisons 1996; HM Inspectorate of Prisons 2013a, b, c, and HM Inspectorate 
of Probation & Prisons 2013 April, May, June). Criminalising these drugs may result in 
greater harm to prisoners rather than supporting their rehabilitation.  
 
To date, little research has focused on service providers’ viewpoints on the drugs services in 
the UK and the current policy which supports them. Therefore, this study looked at how drug 
rehabilitation service providers perceive UK drug policies and how effective they are on 
curtailing criminal behaviours and whether existing policies should be aligned with the 
Portuguese drug liberalisation policy. 
 
Methods  
 
Participants  
 
The target population comprised of 4 service providers from different drug services in the UK 
(summarised in table 1) and consisted of 3 men and 1 woman with approximately 15 years of 
experience in the substance misuse field. All participants were sourced via the internet where 
their details were available on business-orientated social networking services. A purposive 
sampling method was used in order to obtain a suitable sample for this study. 
 
  
 
Table 1: Participant profile summary   
Participant Sex Practice Profession Experience Location 
1 M Substance abuse Counsellor 20 Birmingham 
2 F Reintegration of the target 
population into working sites 
Counsellor/community 
engagement worker 
15 Hampshire 
3 M Drug replacement therapy Community drug and 
alcohol recovery nurse 
14 Surrey 
4 M Rehabilitation centre Project worker/CBT 
specialist 
10 Manchester 
 
 
  
Materials 
 
A thematic analysis, as described by Braun and Clarke (2006), was conducted in order to gain 
a deeper qualitative understanding of this unknown area. The approach was flexible enough 
to allow participants to discuss their views on drug policy where a number of developing 
themes emerged. In-depth semi-structured interviews were carried out as a data collection 
tool (Willig, 2013). Seven main questions were formulated following a pilot study and 
included, for example, “What do you think about the Portuguese Drug Liberalisation Policy? 
And “If this policy would be implemented in the UK, what impact do you think it would 
have?” 
 
Procedure  
 
Ethical permission was secured via the institutional review board. Participants were then 
approached via social media sites. Following informed consent, interviews took place via 
skype and were audio recorded. Each semi-structured interview lasted approximately 45 
minutes. The interview schedule was initially piloted with one participant in order to confirm 
suitability of questions; where no amendments were made. All participants were ensured 
confidentiality and reminded that they could withdrawal from the study at any point should 
they wish to terminate the interview. The information was stored in accordance with the Data 
Protection Act, 1988. Following each interview, participants were forwarded a debrief form 
including a list of supportive agencies. Recorded interviews were transcribed and thematised 
(Braun and Clarke’s, 2006). This included familiarisation with the transcripts to ensure an in-
depth comprehension of its content. This was followed by coding the data which entailed the 
generation of codes as relevant characteristics of the data.  
 
To verify and refine them, created themes were independently reviewed from narratives. 
Feedback was sought throughout the research process to confirm the accuracy of the 
developing themes from the participants’ viewpoint. This ensured accuracy of the 
researcher’s interpretation of the developing themes, ensuring qualitative validity.  
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Results 
 
Two main superordinate themes emerged from the data (shown in Figure 1) and included the 
relevance of the Portuguese Drug Liberalisation Policy in the UK and a need funded 
systems/integrated approach to the substance misuse field. These yielded a number of 
subordinate themes which highlighted the complexity of substance misuse and drug policy in 
the UK, policy awareness, a need for change in UK drugs policy, narrowed speciality area, 
and vision for improvement. The subordinate themes have been discussed under the main 
subordinate themes.  Both the superordinate and subordinate themes are not mutually 
exclusive but interlinked concepts voiced by the participants in this study.  
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 Figure 1: Thematic map 
 
 
Emerged Themes  
 
Superordinate 1: Need to for change in UK drug policy.  The following subordinate themes 
supported the developing superordinate theme and emphasised the need for change in UK 
drug policy. Themes centred on the dissatisfaction with the Misuse of Drugs Act (1971) and 
the Psychoactive Substances Act (2016) along with having an awareness of, the PDLP 
experience. To expand, all participants were knowledgeable about the PDLP and its impact in 
Superordinate 1.
Need for change in drug 
policy 
Dissatisfaction with the 
Psychoactive Drugs Act 
(2016)
Awareness of PDLP
Learning from PDLP 
experience
Superordinate 2.
An integrated approach 
to UK drug policy
Fragmented mental 
health care services 
Service providers feeling 
isolated  
Transparency in 
substance misuse field 
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the substance misuse field. Participants suggested that they had all read the research on the 
drug liberalisation policy rather than rely on media content.    
 
For example, P1 noted, “From what I read and heard, people can carry drugs for personal 
use legally, and they can buy and have drugs if it’s just for a person’s use and it has been put 
in place since 2001, and it seemed to work for them.” Similarly, P2 claimed that, “The policy 
has decriminalised the drugs in terms for personal use and that’s the opposition for 
consumption of any sort of illicit drug just for personal use.” P4 also stated, “the HIV 
infection rates diminished, the prison intake is diminished for those sorts of crimes, and 
leaving the police to deal with other crimes instead of arresting kids that are trying drugs.”  
 
An emphasis here was made on learning from Portugal’s experience. This included the need 
for establishing why people start using drugs to begin with and how drug users can be 
criminalised.  By employing components of the PDLP, participants suggested that this might 
support drug users into treatment rather than prison being the primary choice. Indeed, by 
decriminalising drugs in the UK (both community and prison) could counterbalance the 
problems caused by the disinvestment in outreach work.   
 
For example, P2 suggested that instead of looking “at the fact that they’re [drug users] 
breaking the law, we could be looking at the reasons why people started using these without 
having to look on the legality….  Less pressure, probably, and. … many people in the prison 
system wouldn’t be there as they wouldn’t be convicted of a crime.” 
 
Indeed, a common theme discussed by participants was the ‘sameness’ of UK drug policies 
since the introduction of the Psychoactive Substances Act (2016). Participants were baffled at 
why the Psychoactive Substances Act (2016) had been introduced when many of the same 
principles have been outlined in the Misuse of Drugs Act (1971).  They discussed that by 
retaining the same drug policy principles highlights the war on drugs which inevitably 
increases drug related criminal activity, unnecessary drug prison incarcerations and drug 
related deaths.  Both drug policies were seen as being ineffective since the development of 
new ‘synthetic’ drugs allow its manufacturers to stay ahead of the law. Further, participants’ 
discussed the financial burden on drug enforcement will become compromised owing to 
financial cuts in the public sector. Another concern voiced by participants was their confusion 
of what constitutes a psychoactive substance and how various substances will be classified as 
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this remains unclear.  Participants discussed the difficulties of controlling and monitoring 
substances as outlined in both the Misuse of Drugs Act (1971) and the Psychoactive 
Substances Act’s (2016) along with the ‘unnecessarily high costs’ incurred to support this.   
 
For example, P1 reported, “the next 5 years for doing the same old things, which is the 
current plan perhaps we should try something different because what we’re doing . . . is not 
really working. . .  And while a new strategy just came out a couple of months ago, some 
issues are still the same. . .  And it feels a bit samey. I think we should give it a go, even if 
would be just in a county, instead of the whole country. We’re spending money in the air as 
we could save it.”   
 
Superordinate theme 2: An Integrated Approach to Drug Policy in the UK depicts how 
participants recognised the complexity of substance misuse and the need for an integrated 
system. Similarly to the Kings Fund (2012), participants stated that a lack of consistency in 
mental health knowledge along with institutional and professional separation can lead to a 
lack of cohesion in health care services resulting in missed opportunities to improve care. 
Indeed, as exemplified in the Office for National Statistics (2016), participants made 
reference to how deaths involving heroin or morphine had doubled in the last three years.  
Participants referred to a general lack of communication and transparency in healthcare as 
fragmented, inconsistent and potentially dangerous. 
 
For example, P2 reports, “Different places have different support. For example, in 
Birmingham, there was little concept of the mental health issues that come with drug use. In 
Liverpool, on the other hand, it was all about the mental health issues, and if these were 
addressed, the drug use would be stopped, and this is evident in the service that I worked at. 
In Manchester, we provide the service that is in balance between the two, and that’s why I 
like it. “ 
 
This response highlighted the lack of a single vision on the issue across the UK communities, 
and this factor makes the policies, or even approaching the issue, of fragmentary nature. In 
addition, P2 identified a relevant new paradigm of drug use as a coping strategy for the 
individuals suffering with the mental health issues by specifying that “plenty of people in this 
country are using the prescribed drugs to help them solve their mental health problems.”  
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This highlighted the confusing definition of the Psychoactive Substances Act (2016) which 
includes the effects of drugs impacting alertness, perception of time and space mood or 
empathy with others and/or drowsiness (Gov.uk, 2016). Many dual diagnosed clients which 
are prescribed prescription medication can exhibit these ‘effects/symptoms’. Therefore, 
differentiating between mental health symptoms, prescription medication and the effects of 
psychoactive substances may prove challenging.  Participants argued that there was limited 
evidence based research to support the developing classification of the Psychoactive 
Substances Act (2016), particularly in light of the confusing definition and erratic nature of 
the changing availability of legal highs. Indeed, ‘how can you criminalise a substance when 
you don’t really know what it is’. 
 
The analysis further revealed a range of concerns within the narrow-scope specialties of the 
participants that might be regarded as an indicator of the flawed character of the UK policies 
in general. For example, P4 noted that “the funding is up to the local authorities, who don’t 
really see these issues as a big priority and I worked in different authorities and it’s all more 
or less the same: they don’t look at this issue that can be addressed in a more practice-
orientated way.”  On the other hand, P3 identified a shortcoming in the sphere of substance 
use rehabilitation: “. . . we spend so much time on script [prescribing medications that can be 
addictive] that almost takes us away from actually doing the recovery side of it and 
paperwork as well.”  P2 defined the issues in more general terms as “a wrong starting point” 
since “rules and regulations . . . see these people as criminals rather than people with 
problems.”  Finally, P1 aptly identified such a concern as the lack of collaboration and proper 
communication within the cross-sectional domain and an array of drawbacks that stem from 
this factor:  
 
“. . . there’s no framework, . . . a set of the rules to divide responsibility. Now, everyone is 
working on an island, and they see the other service people on their islands. And the bridge 
between those islands is just not there in place. So, we’ve got confusion, lack of respect, lots 
of misunderstandings, and finally, we still have our duty of care to the people that we’re 
supposed to provide our service to.” 
 
The visionary projections of changes in the UK drug policies varied among participants 
through the lens of their working experiences. Specifically, P3 offered insight into 
transformation with regard to his area of practice, including substitution of “prescribing . . . 
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[for] changing the culture of recovery.”  In contrast, P1 introduced a rather holistic and 
thoughtful view on the issue:  
 
Drug users need care and support; they don’t need criminalising that is taking away their 
hopes for the future about a job, a relationship. Yeah, of course, some will become criminals. 
But I think we can find a better way for most of them, to follow a different path, to find out 
how to get support. They’ve got more problems than drug abuse. Along with P2 and P1’s 
focus on the need for integrated cooperation between the related services, P4 provided an 
important discovery for the field in terms of the potential well-thought-out alternative to the 
current policy:  
 
I think that communication between the services is really important. I often dream of a 
service that can do the whole job, I mean finding employment, housing, social networks etc. 
And if all the services are working as one, it would be much better … And it seems that there 
are big barriers everywhere… if there was more unity in work…, it would be more beneficial 
for everyone. They all should read from the same policy instead of the individual ones.  
 
 Participants highlighted the need for co-operation among different healthcare and social 
providers. There was a general feeling of isolation and not being supported by ‘the system’. 
Participants argued that a biopsychosocial means of supporting substance users rather than 
each service provider working individually would greatly support positive outcomes when 
working with those with a substance use problems. Participants reported that the benefits of 
the health care reform (e.g. Health and Social Care Act, 2012), had not become apparent in 
the substance misuse field and perhaps if existing UK drug policies were aligned with the 
Portuguese drug liberalisation policy, that this would make a positive difference in supporting 
those with substance misuse problems via a systems approach.  
 
Discussion 
 
This study aimed to establish drug service providers’ viewpoints on how effective UK drug 
policies would be on curtailing criminal behaviours and whether existing policies should be 
aligned with the Portuguese drug liberalisation policy. A thematic analysis revealed two 
superordinate themes and included a need for change in UK drug policy including a clearer 
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definition of the Psychoactive Substance Act (2016) and an integrated systems approach to 
drug policy in line with the Portuguese Liberalisation Policy.   
 
Drawing on the findings of the literature review, one has to admit that no universal and 
verified best practice in terms of drug policy exists.  To some extent, the UK’s use of 
regulating the misuse of solvents (Intoxicating Substances Act, 1985) and increasing the use 
of fines and/or cannabis possession has indicated an element of flexibility. However, the UK 
authorities tended to follow criminalisation strategies, at least based on the evidence from the 
1980s to date as outlined in the Misuse of Drugs Act (1971) and the Psychoactive Substances 
Act (2016). Whilst the UK has focused on criminalisation, drug policy in other Countries has 
centred on a harm reduction strategies and hence alternatives to criminal enforcement 
(Demos, 2011).  For example, countries such as Australia and the Netherlands have made 
efforts to decriminalise certain aspects of the drug-based problems, including cannabis issues.  
Various conceptual alternatives can be put into practice, ranging from social and public 
health, as well as reintegration in to society via voluntary or paid work and family support 
among others (Demos, 2011). 
 
Participants did not consider replication but rather learning from Portugal’s experience due to 
the holistic nature of this strategy, which coincided with the opinions by Greenwald (2009), 
Laqueur (2014), Murkin (2014), Felix and Portugal (2015). Similarly to Easton (2016), and 
Humphreys (2013), participants identified a need for change in drug policy in the UK due to 
the ‘sameness’. To expand, participants in this study and in line with Portugal’s drug policies 
suggested that legal penalties for being in possession of drugs, particularly cannabis, should 
be abolished in both the community and in prison. Further, arrest and incarceration should be 
replaced with better and more efficient drug treatment interventions. A significant number of 
those who have substance misuse problems or other mental health problems are imprisoned 
(Hawton, Linsell, Adeniji, Sariaslan et al, 2013; Ministry of Justice, 2008; 2012; 2013a; 
2013b; HMP Inspectorate of Prisons, 1996; HM Inspectorate of Probation and HM 
Inspectorate of Prisons, 2013April, May, June). Government cuts have impacted community 
and prison resources, which makes it difficult for the British Prison System to make the 
necessary improvements following an HM inspectorate’s review. Therefore, this does not 
support drug using prisoners or their throughcare.  Indeed, according to Banbury, Lusher & 
Morgan (2016) in addition to mental health issues, there are limited drugs facilities within 
prison and a lack of support in the community upon release whether drug services or 
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additional mental health care support.  This is particularly concerning since prisoners may 
become re-criminalized in prison for being in possession of a legal high which may impact 
existing prisoner mental health or at the very least compromise their rehabilitation. Further, a 
lack of clarity of what constitutes a legal high may create inconsistencies of prisoner 
prosecution compounded by the limitations of mandatory drug testing to identify these drugs.  
 
In fairness, participants did voice concerns with Portugal’s drug policy centring on 
decriminalisation being associated with higher rates of drugs use and societal problems.   
Whilst it is difficult to establish whether a drug policy from one Country would work in 
another, participants acknowledged that after 5 years if its implementation in Portugal, illegal 
drugs use and rates of new HIV infection and drug deaths had declined (Greenwald, 2009).   
 
Similarly to Reuter (2010), NASW (2013), Passos and Lima (2013) and Ponte (2014) 
participants supported the need for a multifactorial/systems approach to supporting those with 
a substance misuse problem. This research explicated a range of the intertwined issues within 
the UK drug-related system that undermine the efficacy of service delivery, such as (a) lack 
of collaboration and support across the sector, (b) poor communication, (c) differing 
regulations for distinct services, (d) ignorance of mental health issues in this context, (e) one-
sided view on the problem in contrast to its complex nature, and (f) varying approaches both 
county-wide and local levels. In addition, the transition of the problem to the NHS as a single 
sector was found inappropriate due to an already overburdened sector. Participants were 
mindful that a better functioning system requires a clearer understanding of what the system 
is looking for and what its purpose is. This would support information sharing and 
transparency among those who work in the substance misuse field. The CQC might also like 
to guide the substance misuse field with respect to supporting transparency of information in 
working with the Psychoactive Substances Act (2016).  
 
The participants in this study represented different spheres of professional practice within the 
UK drug rehabilitation sector. However, there are no grounds for generalisation of the study 
results based on 4 participants with respect to the entire range of professions in this area. 
Nevertheless, what became apparent was the consistency of participant responses about UK 
drug policies. To expand, participants argued that criminalisation is not the solution to 
addressing substance misuse problems. Indeed, concerns centred on increased drug related 
deaths, more convictions, unnecessary imprisonment, added sentencing and enforcement, all 
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of which are costly. Participants argued that change was needed and implementing the 
Portugal’s drug policy into UK law may support the development of an integrated and 
biopsychosocial systems approach to treatment. We hope that this research provides a plateau 
for further research to be conducted among a broader scope of UK service providers in order 
to develop an evidence base to support the government integrating a comprehensive 
framework into drug policy addressing a systems non- criminalisation approach to substance 
misuse problems.  
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